BlackRock Health Sciences Trust Stock: price and insider trades · United States

From a competitive standpoint, BME sits in a crowded but specialized corner of the market. It competes with other healthcare closed-end funds, sector mutual funds, and healthcare ETFs. Its main differentiators are BlackRock’s scale, sector research depth, and active security selection. The latest publicly disclosed portfolio snapshot shows a large weighting in established leaders such as Johnson & Johnson, Eli Lilly, Merck, AbbVie, Gilead Sciences, Amgen, UnitedHealth Group, Pfizer, Vertex Pharmaceuticals, and Intuitive Surgical. This mix provides exposure across pharmaceuticals, biotechnology, medical devices, and healthcare services, which helps diversify idiosyncratic risk within the sector.

Management continuity is another key point. The trust is led by Erin Xie, PhD, head of BlackRock’s Fundamental Equities Health Sciences team, with Xiang Liu contributing as a co-portfolio manager and sector specialist. That experienced management bench is relevant for investors assessing process stability and research quality. Recent filings and fund disclosures available in 2026 indicate continued use of BlackRock’s discount management program and ongoing shareholder reporting, both important for a listed closed-end structure. For French-speaking investors, the central takeaway is that BME is a NYSE-listed United States healthcare income vehicle with a quality-biased active strategy, but one that can trade at a discount or premium to NAV and therefore requires valuation discipline.